Clinical trials: Food Safety
Mixed Dyslipidemia
Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
- Trial name
- NCT07319559
- Testing
- DW5124, DW5124-R
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Healthy Volunteer
A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
- Trial name
- NCT06717269
- Testing
- NX-5948, Esomeprazole, Famotidine
- Where
- 2 sites in United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Healthy Subjects
A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
The objective of this study is to evaluate the tolerability, safety, and pharmacokinetic of single- and multiple-ascending doses of ID-085 in healthy subjects.
- Trial name
- NCT03372629
- Testing
- ID-085
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Appetite Depressant, Overweight
Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)
The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or…
- Conditions
- Appetite Depressant, Overweight, Body Weight
- Trial name
- NCT01306422
- Testing
- Hoodia gordonii purified extract (H.g.PE)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Healthy
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 474121 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT04194645
- Testing
- BI 474121 tablet, BI 474121 oral solution
- Where
- Germany
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Dry Eye, Evaporative Dry Eye Disease
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction
Dry eye disease (DED) is a common chronic condition characterized by ocular surface discomfort and tear film instability. Evaporative DED associated with meibomian gland dysfunction (MGD) is a frequent phenotype and is often…
- Conditions
- Dry Eye, Evaporative Dry Eye Disease, Meibomian Gland Dysfunction (Disorder)
- Trial name
- NCT07453212
- Testing
- Dietary Supplement: Microbiome-targeted oral supplement
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Varol TUNALI
Infections, Stool Flora
Efficacy and Safety of an Infant Formula With Milkfat and Prebiotics
The purpose of this clinical trial is to evaluate the effect of a new infant starter formula with added prebiotics (GOS) and with a fat blend rich in beta-palmitate.
- Conditions
- Infections, Stool Flora, Stool Biochemistry, Constipation
- Trial name
- NCT01603719
- Testing
- new infant formula with prebiotics and beta-palmitate
- Where
- Germany
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Waldkrankenhaus Protestant Hospital, Spandau
Healthy Volunteers
Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers
A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.
- Trial name
- NCT04715529
- Testing
- FZJ-003
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Clinical Trials, Phase I as Topic
First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080
This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1817080 using a placebo controlled, randomized, single center design.
- Trial name
- NCT02817100
- Testing
- BAY1817080, Itraconazole
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Oral Bioavailability of GLPG0555 in Different Solid Formulations
The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.
- Trial name
- NCT01278095
- Testing
- GLPG0555 solid dispersion, GLPG0555 nanosuspension
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
HIV Infections
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV
This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended safety data for high-risk men. Secondarily, the study will assess the feasibility of conducting the trial and evaluate the preliminary…
- Trial name
- NCT00122512
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Malawi
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- FHI 360
Clinical Trials, Phase I as Topic
BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect
This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design.
- Trial name
- NCT03212586
- Testing
- BAY1902607
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
Food Effect Study of AG-221 in Healthy Male Subjects
AG-221 is a first-in-class drug targeted specifically to inhibit the IDH2 enzyme. Small molecule inhibition of the IDH enzyme represents a new, targeted approach to cancer treatment.
- Trial name
- NCT02218346
- Testing
- AG221
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Healthy Volunteers
A Study of TAK-227 in Healthy Adults
The main aim of this study is to test the effects of food consumption with sponsor compound TAK-227 in healthy participants. The study will also measure side effects, and to check how much TAK-227 stays in the blood over time to…
- Trial name
- NCT05818956
- Testing
- TAK-227
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Allergy, Peanut, Peanut Allergy
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients.
- Conditions
- Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis
- Trial name
- NCT05695261
- Testing
- Microbial Transplantation Therapy, Antibiotic, Oral Immunotherapy (OIT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rima Rachid
Educational Problems
Food Safety, Security and Waste Prevention Intervention on the KAB-P Approach of University Students
The goal of this clinical trial is aimed to examine the effect of food safety and security and waste reduction education on the knowledge, attitudes, behavior, and practices of undergraduates.
- Trial name
- NCT05877495
- Testing
- Nutritional Education Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Selcuk University
Healthy
Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants
The purpose of this study is to investigate the safety, tolerability, food effect as well as the pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and how it is removed from the body…
- Trial name
- NCT01106469
- Testing
- JNJ-41443532
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Ischemic Stroke
Safety and Feasibility of NRICM301 Added to Usual Care for Adults With Acute Ischemic Stroke
Acute ischemic stroke occurs when blood flow to part of the brain is blocked. This study will assess the safety and feasibility of adding NRICM301, a food-grade formula also called Taiwan Xingnao No.
- Trial name
- NCT07900503
- Testing
- NRICM301
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- En Chu Kong Hospital
Healthy Adult Subjects
Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending single doses in healthy adult male and female subjects.
- Trial name
- NCT01364441
- Testing
- ONO-2952
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ono Pharma USA Inc
Healthy Subjects
A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults
- Trial name
- NCT02905253
- Testing
- AC-084
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.